PDF(Pubmed)
Abstract：
This study evaluated prospective associations of ibogaine and 5-MeO-DMT treatment for risky alcohol use and post-traumatic stress disorder (PTSD) symptoms among United States (US) Special Operations Forces Veterans (SOFV). Data were collected during standard clinical operations at pre-treatment and 1-month (1 m), 3-months (3 m), and 6-months (6 m) post-treatment in an ibogaine and 5-MeO-DMT treatment program in Mexico. Of the 86 SOFV that completed treatment, 45 met criteria for risky alcohol use at pre-treatment (mean age = 44; male = 100%; White = 91%). There was a significant reduction in alcohol use from pre-treatment (M = 7.2, SD = 2.3) to 1 m (M = 3.6; SD = 3.5) post-treatment, which remained reduced through 6 m (M = 4.0; SD = 2.9; p < .001, partial eta squared = .617). At 1 m, 24% were abstinent, 33% were non-risky drinking, and 42% were risky drinkers. At 6 m, 16% were abstinent, 31% were non-risky drinking, and 53% were risky drinkers. There were no differences between responders (abstinent/non-risky drinkers) and non-responders (risky drinkers) in demographics/clinical characteristics. However, there were significant and very large differences between responders and non-responders in PTSD symptom (p < .01, d = -3.26) and cognitive functioning change (p < .01, d = -0.99). Given these findings, future clinical trials should determine whether psychedelic-assisted therapy holds promise for individuals with complex trauma and alcohol misuse who have not been successfully treated with traditional interventions.
摘要：
这项研究评估了美国（US）特种作战部队退伍军人（SOFV）中ibogaine和5-MeO-DMT治疗与危险饮酒和创伤后应激障碍（PTSD）症状的前瞻性关联。在治疗前和1个月（1m）的标准临床手术期间收集数据，3个月（3米），以及在墨西哥的ibogaine和5-MeO-DMT治疗计划中治疗后6个月（6m）。在完成治疗的86例SOFV中，45人在治疗前符合危险饮酒标准（平均年龄=44；男性=100％；白人=91％）。从治疗前（M=7.2，SD=2.3）到治疗后1m（M=3.6；SD=3.5），酒精使用量显着减少，它仍然减少了6米(M=4.0；SD=2.9；p<.001，部分eta平方=.617)。在1米,24%是禁欲的，33%的人没有饮酒风险，42%是危险的饮酒者。在6米，16%是禁欲的，31%的人没有饮酒风险，53%是危险的饮酒者。在人口统计学/临床特征方面，响应者（戒断/非风险饮酒者）和非响应者（风险饮酒者）之间没有差异。然而,在PTSD症状（p<.01，d=-3.26）和认知功能变化（p<.01，d=-0.99）方面，应答者和非应答者之间存在显着差异。鉴于这些发现,未来的临床试验应确定迷幻药辅助治疗对复杂创伤和酒精滥用患者是否有希望,这些患者尚未通过传统干预措施成功治疗.
